Additional androgen deprivation makes the difference

@article{Schiffmann2014AdditionalAD,
  title={Additional androgen deprivation makes the difference},
  author={J. Schiffmann and Hans Lesmana and P. Tennstedt and B. Beyer and K. Boehm and V. Platz and D. Tilki and G. Salomon and C. Petersen and A. Kr{\"u}ll and M. Graefen and R. Schwarz},
  journal={Strahlentherapie und Onkologie},
  year={2014},
  volume={191},
  pages={330-337}
}
  • J. Schiffmann, Hans Lesmana, +9 authors R. Schwarz
  • Published 2014
  • Medicine
  • Strahlentherapie und Onkologie
    • BackgroundThe role of additional androgen deprivation therapy (ADT) in prostate cancer (PCa) patients treated with combined HDR brachytherapy (HDR-BT) and external beam radiotherapy (EBRT) is still unknown.Patients and methodsConsecutive PCa patients classified as D’Amico intermediate and high-risk who underwent HDR-BT and EBRT treatment ± ADT at our institution between January 1999 and February 2009 were assessed. Multivariable Cox regression models predicting biochemical recurrence (BCR) were… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    12 Citations
    Highly Influencial Citations
    1
    Background Citations
    7
    Methods Citations
    1
    Results Citations
    1
    12 Citations
    Citation Type

    Citation Type

    Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy
    • 1
    American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.
    • 26
    • Highly Influenced
    • PDF
    Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy
    • 16
    Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    • 12
    Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer
    • 4
    • PDF
    High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes.
    • 18
    Impact of androgen deprivation therapy on apparent diffusion coefficient and T2w MRI for histogram and texture analysis with respect to focal radiotherapy of prostate cancer
    • 5
    • PDF
    Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer
    • 4
    Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?
    • 17
    PSA bounce after 125I-brachytherapy for prostate cancer as a favorable prognosticator
    • 7

    References

    SHOWING 1-10 OF 35 REFERENCES
    High-dose-rate interstitial brachytherapy in combination with androgen deprivation therapy for prostate cancer
    • 19
    Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy
    • 26
    • PDF
    Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.
    • 344
    Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    • 213
    Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease.
    • A. D'Amico, B. J. Moran, +5 authors M. Chen
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2009
    • 70
    • Highly Influential
    Excellent Results From High Dose Rate Brachytherapy and External Beam for Prostate Cancer are Not Improved by Androgen Deprivation
    • 57
    Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy.
    • 21
    Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
    • 825
    6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer: A Randomized Controlled Trial
    • 202
    Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
    • 723